Secondary acute myeloblastic leukaemia (AML) (expressing 11q23 mutation) occurring 11 months after chemotherapy/radiotherapy for paediatric non-Hodgkin lymphoma (NHL)

Clinical Oncology

Volumn 12, Issue 2, 2000, Pages 112-114

  Taylor, H J H ^a   Gravett, P ^b   Plowman, P N ^a,c  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b London Clinic Cancer Centre   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

11q23 mutation; Acute myeloblastic leukaemia (AML); Non Hodgkin lymphoma (NHL)

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CHROMOSOME 11Q; CHROMOSOME MUTATION; FEMALE; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE;

EID: 0034018957     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2000.9128     Document Type: Article

References (11)

1. Andersen MK, Johansson B, Larsen SO, et al. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements. Haematologica 1998; 83:483-8.
2. Pedersen-Bjergaard J, Philip P, Larson SO, et al. Therapy-related myelodysplasia and acute myeloid leukaemia. Cytogenetic characteristics of 115 consecutive cases and risks in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen Series. Leukaemia 1993;7:1975-86.
3. Pierce DA, Shimuzu Y, Preston DL, Vaeth M, Mabuchi K. Studies of the mortality of atomic bomb survivors; report 12 part 1: cancer 1950-1990. Radiat Res 1996;146:1-27.
4. Pedersen-Bjergaard J, Pedersen M, Roulston D, et al. Different genetic pathways in leukaemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukaemia. Blood 1995;86:3542-52.
5. Levine EG, Bloomfield CD. Leukaemias and myelodysplastic syndromes secondary to drug, radiation and environmental exposure. Semin Oncol 1992;19:47-84.
6. Van Leeuwen FE. Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. Baillieres Clin Haematol 1996;9:1305-12.
7. Rowley JD, Golomb HM, Vardiman J. Nonrandom chromosomal abnormalities in acute nonlymphocytic leukaemiain patients treated for Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1977;50:759-70.
8. Secker-Walker LM, Moorman AV, Bain BJ, et al., on behalf of the EU Concerted Action 11q23 Workshop. Secondary acute leukaemia and myelodysplastic syndrome with 11q23 abnormalities. Leukaemia 1998;12:840-4.
9. Micallef I, Lillington D, Apostolidis J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukaemia following high dose therapy with autologous haemopoietic progenitor cell support for lymphoid malignancies. J Clin Oncol. In press.
10. Partridge SE, Lowdell CP. Myelodysplastic syndrome as a complication of neoadjuvant triple M chemotherapy and radiotherapy. Clin Oncol 1999;11:187-9.
11. Kollmannsberger C, Hartmann JT, Kanz L, et al. Risk of secondary myeloid leukaemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol 1998;124:207-14.